Autopsy report · NCT02464631

To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis

“In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 62 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Institute of Liver and Biliary Sciences, India

Sponsor type

University, hospital or other

Conditions

HCV Related Cirrhosis

Interventions

Sofosbuvir + Ribavirin 1; Sofosbuvir + Ribavirin 2; Sofosbuvir + Ribavirin 3

Participants

62

Sites

1

Countries

India

Trials that died the same way

• Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia
  “Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.